Aurinia Pharmaceuticals Inc. announced that it has selected Worldwide Clinical Trials as its Clinical Research Organization (CRO) for the AURORA Phase 3 study of volcosporin for the treatment of active lupus nephritis (LN). 'Selecting a CRO for AURORA is a key milestone for Aurinia following the successful end-of-Phase 2 meeting with the U.S. Food &Drug Administration (FDA) Division of Pulmonary, Allergy and Rheumatology Products. With support from Worldwide, Aurinia will proceed with conducting a randomized, placebo-controlled, double-blind global 52-week trial in approximately 320 patients. The primary endpoint as in the Phase 2b AURA trial is renal response (complete remission), at 24 weeks. In addition to the assessment of renal response, a key marker of clinical benefit in this population is the duration of proteinuria improvement. Therefore, secondary endpoints will include the duration of renal response at 52 weeks (48 weeks in AURA), an efficacy measure which delineates durability of renal response (remission), an important parameter in evaluating long-term outcomes for the treatment of LN.